Among other changes, a 2022 update to a KDIGO guideline recommends weight management as a foundational lifestyle for patients with diabetes and kidney disease. Updated KDIGO guidelines place a ...

Medically reviewed by Kashif J. Piracha, MDMedically reviewed by Kashif J. Piracha, MD Diabetic nephropathy is a form of long-term, chronic kidney disease resulting from having had diabetes for ...

Survival models using electronic health record data show promise in predicting progression to proliferative diabetic ...

How Is IgAN Usually Managed, and Where Does Vanrafia Fit In? A group of kidney experts, called KDIGO, publishes recommendations on how to treat many different kidney diseases, including IgAN ...

Diabetic nephropathy is the leading cause of kidney disease in patients starting renal replacement therapy and affects ~40% of type 1 and type 2 diabetic patients. It increases the risk of death ...

On the other hand, podocytes are the culprits in diabetic nephropathy in that a reduced nephrin expression may lead to podocyte foot process broadening and effacement, while increased VEGF ...

The Kidney Disease: Improving Global Outcomes (KDIGO) 2020 guideline informs the management of patients with diabetes and chronic kidney disease.

Panelists discuss how emerging targeted therapies for immunoglobulin A (IgA) nephropathy address critical gaps in the current treatment landscape by offering disease-modifying potential, improved ...

The KDIGO guidelines state that glycaemic control should be part of a multifactorial intervention strategy that addresses blood pressure control and cardiovascular risk, and involves the use of ...

These results provide insight into how PB5 treatment improves diabetic symptoms and possibly serves as a novel protective measure and therapeutic strategy in the treatment of type 2 diabetes.

Diabetic kidney disease is the leading cause of end-stage renal disease in the U.S., and 50% of adults initiating renal replacement therapy have diabetes, according to the CDC.Additionally ...